Stocks News

LAST PRICE
246.8000
TODAY'S CHANGE (%)
Trending Down-1.9900 (-0.7999%)

Bid / Lots
241.1800/ 1
Ask / Lots
252.4000/ 1
Open / Previous Close
247.4600 / 248.7900
Day Range
Low 245.3200
High 250.7100
52 Week Range
Low 141.9750
High 304.3900
Volume
687,266
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 18, 2024
- DJ Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler, from 1:10PM ET on Monday Nov 18, 2024 by Dow Jones
  1:10PM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: ALNY
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 18, 2024 13:10 ET (18:10 GMT)
- DJ Alnylam Pharmaceuticals Price Target Maintained With a $400.00/Share by HC Wainwright & Co., from 12:59PM ET on Monday Nov 18, 2024 by Dow Jones
  12:59PM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: ALNY
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ALNY/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 18, 2024 12:59 ET (17:59 GMT)
- Alnylam Pharmaceuticals Says Nucresiran Performed Well in Phase 1 Transthyretin Amyloidosis Study, from 3:42AM ET on Monday Nov 18, 2024 by MT Newswires
  3:42AM ET on Monday Nov 18, 2024 by MT Newswires
  Companies Mentioned: ALNY
  03:42 AM EST, 11/18/2024 (MT Newswires) -- Alnylam Pharmaceuticals (ALNY) said Sunday its phase 1 study of nucresiran as a potential treatment for transthyretin amyloidosis showed the drug's efficacy. Transthyretin amyloidosis is a condition charact...
Nov 17, 2024
- Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose, from 9:30AM ET on Sunday Nov 17, 2024 by Dow Jones
  9:30AM ET on Sunday Nov 17, 2024 by Dow Jones
  Companies Mentioned: ALNY
  
  relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
Nov 12, 2024
- Alnylam Pharmaceuticals Shares Fall After Wolfe Downgrade, from 2:23PM ET on Tuesday Nov 12, 2024 by MT Newswires
  2:23PM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: ALNY
  02:23 PM EST, 11/12/2024 (MT Newswires) -- Alnylam Pharmaceuticals (ALNY) shares were down more than 3% in recent Tuesday trading after Wolfe downgraded the stock to underperform from peer perform. Trading volume stood at about 505,000 shares agains...

Yesterday
- Prestige Consumer Healthcare Insider Sold Shares Worth $898,241, According to a Recent SEC Filing, from 10 hours ago by MT Newswires
  10 hours ago by MT Newswires
  Companies Mentioned: PBH
Nov 20, 2024
- John Elway Teams Up with Endo to Share Update on Dupuytren's Contracture and Treatment with XIAFLEX® (collagenase clostridium histolyticum), from 8:50AM ET on Wednesday Nov 20, 2024 by CNW Group
  8:50AM ET on Wednesday Nov 20, 2024 by CNW Group
  Companies Mentioned: NDOI
- John Elway Teams Up with Endo to Share Update on Dupuytren's Contracture and Treatment with XIAFLEX(R) (collagenase clostridium histolyticum), from 8:50AM ET on Wednesday Nov 20, 2024 by PR Newswire
  8:50AM ET on Wednesday Nov 20, 2024 by PR Newswire
  Companies Mentioned: NDOI
Nov 18, 2024
- Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling, from 5:30PM ET on Monday Nov 18, 2024 by PR Newswire
  5:30PM ET on Monday Nov 18, 2024 by PR Newswire
  Companies Mentioned: NDOI
- Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling, from 5:30PM ET on Monday Nov 18, 2024 by Dow Jones
  5:30PM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: NDOI
Nov 15, 2024
- Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada, from 7:30AM ET on Friday Nov 15, 2024 by CNW Group
  7:30AM ET on Friday Nov 15, 2024 by CNW Group
  Companies Mentioned: NDOI
- Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora(R) Cream in Canada, from 7:30AM ET on Friday Nov 15, 2024 by PR Newswire
  7:30AM ET on Friday Nov 15, 2024 by PR Newswire
  Companies Mentioned: NDOI
- Prestige Consumer Healthcare Insider Sold Shares Worth $2,024,499, According to a Recent SEC Filing, from 3:27AM ET on Friday Nov 15, 2024 by MT Newswires
  3:27AM ET on Friday Nov 15, 2024 by MT Newswires
  Companies Mentioned: PBH
Nov 14, 2024
- Royalty Pharma Announces Inaugural Prize for Impact in Healthcare, from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
  4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: RPRX
Nov 11, 2024
- DJ Prestige Consumer Hlthcr Is Maintained at Buy by DA Davidson, from 11:48AM ET on Monday Nov 11, 2024 by Dow Jones
  11:48AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: PBH

Alnylam Pharmaceuticals Inc
NASDAQ:ALNYUnited States

Search Criteria

Nov 18, 2024

DJ Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler, from 1:10PM ET on Monday Nov 18, 2024 by Dow Jones

DJ Alnylam Pharmaceuticals Price Target Maintained With a $400.00/Share by HC Wainwright & Co., from 12:59PM ET on Monday Nov 18, 2024 by Dow Jones

Alnylam Pharmaceuticals Says Nucresiran Performed Well in Phase 1 Transthyretin Amyloidosis Study, from 3:42AM ET on Monday Nov 18, 2024 by MT Newswires

Nov 17, 2024

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose, from 9:30AM ET on Sunday Nov 17, 2024 by Dow Jones

Nov 12, 2024

Alnylam Pharmaceuticals Shares Fall After Wolfe Downgrade, from 2:23PM ET on Tuesday Nov 12, 2024 by MT Newswires

Peers Headlines

Yesterday

Prestige Consumer Healthcare Insider Sold Shares Worth $898,241, According to a Recent SEC Filing, from 10 hours ago by MT Newswires

Nov 20, 2024

John Elway Teams Up with Endo to Share Update on Dupuytren's Contracture and Treatment with XIAFLEX® (collagenase clostridium histolyticum), from 8:50AM ET on Wednesday Nov 20, 2024 by CNW Group

John Elway Teams Up with Endo to Share Update on Dupuytren's Contracture and Treatment with XIAFLEX(R) (collagenase clostridium histolyticum), from 8:50AM ET on Wednesday Nov 20, 2024 by PR Newswire

Nov 18, 2024

Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling, from 5:30PM ET on Monday Nov 18, 2024 by PR Newswire

Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling, from 5:30PM ET on Monday Nov 18, 2024 by Dow Jones

Nov 15, 2024

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada, from 7:30AM ET on Friday Nov 15, 2024 by CNW Group

Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora(R) Cream in Canada, from 7:30AM ET on Friday Nov 15, 2024 by PR Newswire

Prestige Consumer Healthcare Insider Sold Shares Worth $2,024,499, According to a Recent SEC Filing, from 3:27AM ET on Friday Nov 15, 2024 by MT Newswires

Nov 14, 2024

Royalty Pharma Announces Inaugural Prize for Impact in Healthcare, from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 11, 2024

DJ Prestige Consumer Hlthcr Is Maintained at Buy by DA Davidson, from 11:48AM ET on Monday Nov 11, 2024 by Dow Jones